Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...

The FDA has approved brensocatib tablets in 10-mg and 25-mg doses as once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children aged 12 years or older, according to a ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has approved Insmed's daily pill brensocatib, which will be sold under the ...

— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — NCFB is a chronic and progressive disease that can lead to permanent lung ...

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses ...

Rev-56 scientific leader promoted to CSO to advance Revagenix’s scientific strategy in non-cystic fibrosis bronchiectasis and ...

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Renovion Inc., a biopharmaceutical company focused on developing therapies to restore lung health in individuals with mucus-related lung diseases, announced topline ...

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...

The European Medicines Agency (EMA) has recommended granting marketing authorization in the EU for brensocatib (Brinsupri, Insmed Incorporated) for non-cystic fibrosis bronchiectasis (NCFB) in ...

In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...

Credit: Insmed. Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1. Treatment with brensocatib 10mg and 25mg significantly reduced the annual rate of pulmonary exacerbations in ...